Autism Spectrum Disorder (ASD) Treatment Market Projected To Grow At A CAGR of 4.6% During The Forecast Period 2020 - 2025

Advancement in technology resulting in E learning program to create awareness every corner of the world coupled with growing number generic pharmaceutical product for autism treatment and pipeline drugs is anticipated to drive the Autism Spectrum Disorder (ASD) Treatment Market during the forecast period 2020-2025. Autism Spectrum Disorder (ASD) Treatment Market size was valued at $ 3.3 Billion by 2019, and is anticipated to grow at a CAGR of 4.6% during the forecast period 2020-2025.

The Autism Spectrum Disorder (ASD) Treatment Market growth rate is attributed to the growing prevalence of autism and pervasive developmental disorder (PDD) and rising awareness about autism among the patient population is anticipated to bring new opportunities. Autism spectrum disorder is a disability that causes significant social, communication, and behavioral challenges. The severity of the disorder differs from person to person. It can involve mild symptoms to severe disability wherein extensive support is required. Autism spectrum disorders are lifelong developmental disabilities. The word ‘spectrum’ represents the range and severity of autism among different people. The cause of autism spectrum disorder is uncertain, but possible factors include discrepancies in the development of certain brain functions and the heredity. Early identification, assessment, and diagnosis is the first step toward the treatment of autism spectrum disorder.

Furthermore, rise in the number of government-sponsored awareness programs for autism, innovation of new products, increase in the number of autism patients, and growing research & development activities are key factors driving the global autism spectrum disorder treatment market. The advancement in technology has results in E learning program to create awareness every corner of the world. Growing number generic pharmaceutical product for autism treatment and pipeline drugs are another key fueling factors for autism spectrum disorder treatment market. On the other hand, stricter regulations on product approval are the key restraint for the global autism spectrum disorder treatment market.

North America is the major region dominating the Autism Spectrum Disorder (ASD) Treatment Market with revenue of $1,850.8m in 2019 and is forecast to grow at a fastest CAGR of 5.1% during the forecast period of 2020-2025 to generate revenue of $2,364.2m in 2025. Furthermore, U.S. in North America region is dominating the Autism Spectrum Disorder (ASD) Treatment Market generating revenue of $1,512.8m in 2019 and is set to reach $1,988.3m by 2025 growing at a fastest CAGR of 5.6% during the forecast period 2020-2025. This is owing to presence of major market players, availability of advanced medical facility and technological advancement in terms of screening process.

Also, Autistic Disorder accounted for major share in 2019. This segment generated revenue of $1,460.5m in 2019 and is forecast to be growing at fastest CAGR of 5.5% during the forecast period 2020-2025. This segment is projected to generate revenue of $1,910.7m by 2025. This is owing to high prevalence of Autistic Disorder disease type. While significant developments have been made in a number of educational, psychosocial, and biological approaches, there is a lack of understanding of the comparative and cumulative effectiveness of the different treatment modalities. In particular, from the viewpoint of parents, funding and continuity of programmes need change and improvements. According to recent studies, timely evaluation and identification of AD among young children continue to be important public health goals as various research evidence links early treatment and services for AD with improved outcomes. Risperidone and aripiprazole are currently the only two FDA-approved drugs for treating AD, but as the researchers pointed out, they don’t address core AD symptoms, and can have considerable adverse side effects.

The Autism Spectrum Disorder (ASD) Treatment market is poised to receive upswing owing to increasing in Government funding and focus on autism specific programs government keeps a path toward new autism discoveries and support. Autism appropriations to ensure federal agencies that run programs for autism research, services and supports are appropriately funded by the government in order to provide better facility.

Government are launching new different programs and funding and collaboration in that program are increasing in order to monitor the number of characteristics of children with Autism Spectrum Disorder and development disabilities in multiple communities throughout the world. U.S Center for disease control and prevention (CDC) will invest more than $16 million over the next four years to enhance tracking in their program named as Autism and Developmental Disabilities Monitoring (ADDM).

Increasing research towards making novel drugs for the treatment of Autism spectrum disorders in order to block a receptor for the hormone vasopressin in the brain that has been linked to control of socialization, stress, anxiety and aggression has been successfully made. This drug is thus being effective in children over the age of 5 and adolescents with Autism Spectrum Disorders (ASD). Bumetanide a prescription drug  improves some of symptoms in young children with Autism Spectrum Disorder (ASD) and has no significant side effects . Manufacturing are increasing focus on preparing a drug that improves the symptoms of ASD by the decreasing the ratio of GABA(act as a neurotransmitter) to glutamate in brain.

Increasing number of Drugs in order to improve social learning and reduce  Autism Spectrum Disorder (ASD) symptoms  during the time when the brains of the children are still developing by adding GABA and glutamate in it for increasing plasticity and learning capabilities in brain such that children should have better opportunities for better and well-being life. This is driving the demand of Autism Spectrum Disorder during the forecast period 2020-2025.

Novartis and Sangamo collaborated to create gene therapies for autism spectrum disorder treatment and other brain disorders. The collaboration will net Sangamo an upfront fee of $75 million with the potential to rake in $720 million, contingent on the Brisbane-based company’s ability to meet developmental and commercial milestones.

The major companies in the Autism Spectrum Disorder (ASD) Treatment market include Bristol-Myers Squibb, Otsuka Holdings Co.Ltd., Novartis AG, Roche Pharmaceuticals, Janssen Pharmaceuticals, Pfizer Inc., Actavis Inc., Autism Therapeutics, Teva Pharmaceuticals, Q BioMed Inc. In September 2017, Risperidone and aripiprazole are currently the only two FDA-approved drugs for treating AD, but as the researchers pointed out, they don’t address core AD symptoms, and can have considerable adverse side effects.

Although there has been product withdrawals and low demand for the product, companies are conducting research and development for the perfecting the medical device. Health professionals are rooting for the comeback of Autism Spectrum Disorder (ASD) Treatment with effective products methods. There are the major factors set to buoy the Autism Spectrum Disorder (ASD) Treatment market during 2020-2025.